185 related articles for article (PubMed ID: 27066749)
1. Structure-Based Design of a Novel SMYD3 Inhibitor that Bridges the SAM-and MEKK2-Binding Pockets.
Van Aller GS; Graves AP; Elkins PA; Bonnette WG; McDevitt PJ; Zappacosta F; Annan RS; Dean TW; Su DS; Carpenter CL; Mohammad HP; Kruger RG
Structure; 2016 May; 24(5):774-781. PubMed ID: 27066749
[TBL] [Abstract][Full Text] [Related]
2. Hit identification of SMYD3 enzyme inhibitors using structure-based pharmacophore modeling.
Alnabulsi SM; Al-Shar'i NA
Future Med Chem; 2019 May; 11(10):1107-1117. PubMed ID: 31280673
[No Abstract] [Full Text] [Related]
3. Structural Basis for Substrate Preference of SMYD3, a SET Domain-containing Protein Lysine Methyltransferase.
Fu W; Liu N; Qiao Q; Wang M; Min J; Zhu B; Xu RM; Yang N
J Biol Chem; 2016 Apr; 291(17):9173-80. PubMed ID: 26929412
[TBL] [Abstract][Full Text] [Related]
4. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer.
Mazur PK; Reynoird N; Khatri P; Jansen PW; Wilkinson AW; Liu S; Barbash O; Van Aller GS; Huddleston M; Dhanak D; Tummino PJ; Kruger RG; Garcia BA; Butte AJ; Vermeulen M; Sage J; Gozani O
Nature; 2014 Jun; 510(7504):283-7. PubMed ID: 24847881
[TBL] [Abstract][Full Text] [Related]
5. Smyd3 open & closed lock mechanism for substrate recruitment: The hinge motion of C-terminal domain inferred from μ-second molecular dynamics simulations.
Chandramouli B; Silvestri V; Scarno M; Ottini L; Chillemi G
Biochim Biophys Acta; 2016 Jul; 1860(7):1466-74. PubMed ID: 27085704
[TBL] [Abstract][Full Text] [Related]
6. Lysine methylation in cancer: SMYD3-MAP3K2 teaches us new lessons in the Ras-ERK pathway.
Colón-Bolea P; Crespo P
Bioessays; 2014 Dec; 36(12):1162-9. PubMed ID: 25382779
[TBL] [Abstract][Full Text] [Related]
7. Unveiling the Biochemistry of the Epigenetic Regulator SMYD3.
Fabini E; Talibov VO; Mihalic F; Naldi M; Bartolini M; Bertucci C; Del Rio A; Danielson UH
Biochemistry; 2019 Sep; 58(35):3634-3645. PubMed ID: 31389685
[TBL] [Abstract][Full Text] [Related]
8. Discovery of the SMYD3 Inhibitor BAY-6035 Using Thermal Shift Assay (TSA)-Based High-Throughput Screening.
Gradl S; Steuber H; Weiske J; Szewczyk MM; Schmees N; Siegel S; Stoeckigt D; Christ CD; Li F; Organ S; Abbey M; Kennedy S; Chau I; Trush V; Barsyte-Lovejoy D; Brown PJ; Vedadi M; Arrowsmith C; Husemann M; Badock V; Bauser M; Haegebarth A; Hartung IV; Stresemann C
SLAS Discov; 2021 Sep; 26(8):947-960. PubMed ID: 34154424
[TBL] [Abstract][Full Text] [Related]
9. Therapeutical potential of deregulated lysine methyltransferase SMYD3 as a safe target for novel anticancer agents.
Rajajeyabalachandran G; Kumar S; Murugesan T; Ekambaram S; Padmavathy R; Jegatheesan SK; Mullangi R; Rajagopal S
Expert Opin Ther Targets; 2017 Feb; 21(2):145-157. PubMed ID: 28019723
[TBL] [Abstract][Full Text] [Related]
10. Small-molecule inhibitors of lysine methyltransferases SMYD2 and SMYD3: current trends.
Fabini E; Manoni E; Ferroni C; Rio AD; Bartolini M
Future Med Chem; 2019 Apr; 11(8):901-921. PubMed ID: 30998113
[TBL] [Abstract][Full Text] [Related]
11. In Silico/In Vitro Hit-to-Lead Methodology Yields SMYD3 Inhibitor That Eliminates Unrestrained Proliferation of Breast Carcinoma Cells.
Alshiraihi IM; Jarrell DK; Arhouma Z; Hassell KN; Montgomery J; Padilla A; Ibrahim HM; Crans DC; Kato TA; Brown MA
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33333978
[TBL] [Abstract][Full Text] [Related]
12. Protein lysine methyltransferase SMYD3 is involved in tumorigenesis through regulation of HER2 homodimerization.
Yoshioka Y; Suzuki T; Matsuo Y; Tsurita G; Watanabe T; Dohmae N; Nakamura Y; Hamamoto R
Cancer Med; 2017 Jul; 6(7):1665-1672. PubMed ID: 28639750
[TBL] [Abstract][Full Text] [Related]
13. Structural insights into the autoinhibition and posttranslational activation of histone methyltransferase SmyD3.
Sirinupong N; Brunzelle J; Doko E; Yang Z
J Mol Biol; 2011 Feb; 406(1):149-59. PubMed ID: 21167177
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of the Conformational Change of the Protein Methyltransferase SMYD3: A Molecular Dynamics Simulation Study.
Sun J; Li Z; Yang N
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281237
[TBL] [Abstract][Full Text] [Related]
15. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells.
Hamamoto R; Furukawa Y; Morita M; Iimura Y; Silva FP; Li M; Yagyu R; Nakamura Y
Nat Cell Biol; 2004 Aug; 6(8):731-40. PubMed ID: 15235609
[TBL] [Abstract][Full Text] [Related]
16. Targeting INMT and interrupting its methylation pathway for the treatment of castration resistant prostate cancer.
Zhong S; Jeong JH; Huang C; Chen X; Dickinson SI; Dhillon J; Yang L; Luo JL
J Exp Clin Cancer Res; 2021 Sep; 40(1):307. PubMed ID: 34587977
[TBL] [Abstract][Full Text] [Related]
17. The SMYD3-MAP3K2 signaling axis promotes tumor aggressiveness and metastasis in prostate cancer.
Ikram S; Rege A; Negesse MY; Casanova AG; Reynoird N; Green EM
Sci Adv; 2023 Nov; 9(46):eadi5921. PubMed ID: 37976356
[TBL] [Abstract][Full Text] [Related]
18. Requirement of histone methyltransferase SMYD3 for estrogen receptor-mediated transcription.
Kim H; Heo K; Kim JH; Kim K; Choi J; An W
J Biol Chem; 2009 Jul; 284(30):19867-77. PubMed ID: 19509295
[TBL] [Abstract][Full Text] [Related]
19. Crystal structures of the human histone H4K20 methyltransferases SUV420H1 and SUV420H2.
Wu H; Siarheyeva A; Zeng H; Lam R; Dong A; Wu XH; Li Y; Schapira M; Vedadi M; Min J
FEBS Lett; 2013 Nov; 587(23):3859-68. PubMed ID: 24396869
[TBL] [Abstract][Full Text] [Related]
20. Structure of human lysine methyltransferase Smyd2 reveals insights into the substrate divergence in Smyd proteins.
Xu S; Zhong C; Zhang T; Ding J
J Mol Cell Biol; 2011 Oct; 3(5):293-300. PubMed ID: 21724641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
